negatives of retatrutide Diagram showing the mechanism action of 30 Days of Retatrutide —
Description
Additionally, pharmacovigilance analyses using the FDA Adverse Event Reporting System (FAERS) noted an increased number of thyroid-related reports, including hyperplasia and neoplasms, associated with GLP-1 receptor agonists
Another limitation of GLP-1 RAs is that discontinuation commonly leads to substantial body weight regain, and many patients who regain weight subsequently restart GLP-1 RA therapy, resulting in a recurrent cycle of body weight loss and gain [10]
That's by design
N Engl J Med 384 , 9891002 (2021)
